NT-proBNP accurately identified reduced LVEF (AUC 0.805) with 71.3% sensitivity and 77.8% specificity at a threshold of 1562 pg/mL in patients with CKD stages 3-5.
Observational (n=840)
No
Does the use of CKD stage-specific NT-proBNP thresholds improve the diagnostic accuracy for detecting reduced left ventricular ejection fraction in patients with chronic kidney disease?
A single NT-proBNP diagnostic threshold is inadequate for patients with CKD; applying stage-specific cut-off values significantly improves the diagnostic precision for detecting reduced left ventricular ejection fraction.
Effect estimate: AUC 0.805 (95% CI 0.7549-0.8400)
Absolute Event Rate: 71.3% vs 77.8%
p-value: p=<0.001
NT-proBNP is a useful marker for detecting systolic dysfunction in patients with CKD. However, a single diagnostic threshold is inadequate; stage-specific cut-off values improve diagnostic precision, particularly in early-to-moderate CKD, and may facilitate earlier referral for echocardiographic evaluation.
Eren et al. (Fri,) conducted a observational in Patients with chronic kidney disease stages 3 to 5 undergoing NT-proBNP measurement and echocardiographic evaluation (n=840). NT-proBNP measurement vs. Reduced LVEF (LVEF <50%) vs preserved LVEF (LVEF ≥50%) was evaluated on Diagnostic performance of NT-proBNP to detect reduced left ventricular ejection fraction (LVEF <50%) (AUC 0.805, 95% CI 0.7549-0.8400, p=<0.001). NT-proBNP accurately identified reduced LVEF (AUC 0.805) with 71.3% sensitivity and 77.8% specificity at a threshold of 1562 pg/mL in patients with CKD stages 3-5.